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Purpose: Acidic fibroblast growth factor (aFGF) is a potent mitogen for vascular and 
other mesenchymal cells in vitro that can induce angiogenesis in vivo. Although heparin 
has no mitogenic potential of its own, it is an important aFGF cofactor in vitro and may 
also be capable of stimulating angiogenesis. Because the development of a collateral 
vasculature in response to ischemia ppears to be dependent on angiogenesis, we com- 
pared the abilities of aFGF with or without heparin and heparin alone to accelerate 
angiogenesis in a rat hind limb ischemia model. 
Methods: Daily subcutaneous injections of saline solution (1 ml), heparin (0.05 mg), or 
human recombinant aFGF with or without heparin (1 wg aFGF, 0.05 mg heparin) were 
administered into the hind limb region distal to the point of unilateral femoral artery 
ligation in the rat for the 10 days immediately after vascular occlusion. Angiogenicity was 
determined by histologic assessment of treatment outcomes. 
Results: Histologic assessment of the number of vessels per microscopic feld 10 days after 
vascular ligation in the fibrofatty tissues distal to the ligation point had the following 
results: saline solution, 10 --- 4 vessels; heparin, 13 --- 4 vessels (p < 0.05 vs saline 
solution); aFGF, 26 -+ 8 vessels; and aFGF/heparin 36 --. 8 vessels (aFGF, aFGF/  
heparin, p < 0.001 vs saline solution). Similar increases in vascularization were also noted 
in the skeletal muscle tissues distal to the vascular ligation point. Immunohistochemical 
analysis for the presence of proliferating cell nuclear antigen, a marker for mitogenic 
activity, demonstrated corresponding increases in proliferating cell nuclear antigen label- 
ing for each of the treatment groups, expressed as a percentage of total vascular cell 
nuclei, as follows: saline solution, 7% -+ 2%; heparin, 21% +-. 8% (p < 0.05 vs saline 
solution); aFGF, 67% +- 9%; and aFGF/heparin, 83% - 5% (aFGF, aFGF/heparin, p < 
0.001 vs saline solution). 
Conclusions: The increased vascularization and mitogenic activity demonstrated by these 
respective studies uggest that angiogenesis is significantly accelerated by the administra- 
tion ofheparin alone and is accelerated to a greater extent by the administration of aFGF 
with or without heparin. The aFGF/heparin regimen may represent an optimal means of 
augmenting collateral vessel growth to relieve ischemia in the clinical setting. (J Vasc Surg 
1997;26:302-12.) 
Angiogenesis appears to be an important compo- 
nent of  the biologic response to ischemia, resulting 
in the development of a collateral vasculature. 1,2 This 
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response, however, has been shown in a number of 
clinical and animal models to be delayed in onset and 
often incomplete in reconstituting perfusion to nor- 
mal levels. 3-9 The ability to significantly augment or 
accelerate angiogenesis could therefore be of signifi- 
cant benefit in the setting of acute or chronic isch- 
emia caused by atherosclerosis or other vascular oc- 
clusive processes. Such a strategy of "therapeutic 
angiogenesis" might be a useful adjunct or alterna- 
tive to angioplasty, bypass grafting, or other conven- 
tional revascularization procedures. Conceivably, the 
successful application of angiogenic therapy could 
significantly advance the treatment of peripheral or 
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myocardial ischemia, wound healing, or other condi- 
tions that require neovascularization or tissue regen- 
eration s-l° and provide a "biologic" approach to the 
treatment of these conditions. 
Acidic fibroblast growth factor (aFGF) is a mem- 
ber of the fibroblast (heparin-binding) growth factor 
family of polypeptides and is a potent mitogen for a 
variety ofmesenchymal and neuroectodermal cel s in 
vitro, including those of vascular origin. 11 Heparin is 
a critical cofactor for aFGF in vitro, although it has 
no mitogenic potential of its own. 12 The enhance- 
ment of the mitogenic potential ofaFGF by heparin 
may be in part related to the ability of heparin to 
protect FGF from heat and proteolytic inactiva- 
tion, x3,~4 or it may be related to other heparin-de- 
pendent interactions between FGF and the target 
cell 15,16 or with the extracellular matrix. 17-2° Because 
aFGF is produced by mesenchymal cells and appears 
to be sequestered in the extracellular matrix, heparin 
administration might promote an angiogenic re- 
sponse in vivo through an interaction with, and en- 
hancement of, the mitogenic effects of endogenous 
FGF. 
Although aFGF and heparin have each been 
shown to induce angiogenesis in several models, re- 
suits have been conflicting; several studies failed to 
demonstrate increased angiogenesis with administra- 
tion of these substances. 4,7,9,11,21-2s The relative an- 
giogenic potential of heparin, aFGF, and aFGF with 
heparin has also not previously been assessed. Fur- 
thermore, because mitogenic assays have not gener- 
ally been included in these previous tudies, it is not 
possible to determine whether these studies have 
demonstrated the stimulation of true angiogenesis, 
as opposed to the distention or recruitment of a 
preexistent, nascent vasculature. These consider- 
ations are particularly relevant in light of the antico- 
agulant properties of heparin and the vasodilator 
properties of both these agents. To address these 
issues, we examined the relative efficacy of heparin, 
aFGF, and aFGF with heparin in stimulating anglo- 
genesis in a model of peripheral vascular ischemia 
using histologic analyses of tissue vascularization a d 
mitogenicity. 26,27 
MATERIALS AND METHODS 
Model preparation. A model of peripheral isch- 
emia was created using acute occlusion of the femo- 
ral artery in 250 g male Sprague Dawley rats, as 
previously described. 26For these experiments, four 
animals were housed per cage with free access to food 
and water. The animals were treated according to the 
National Research Council's animal care regulations 
and with the approval of the institutional review 
board of Cornell University Medical College. The 
animals were anesthetized with sodium pentobarbital 
(0.1 ml/100 g of 64.8 mg/ml stock) via intraperito- 
neal injection. The left groin area was haved and 
prepped with Betadine. A transverse incision of 
about 1 inch was made over the left femoral artery. 
The incision was held open with a self-retaining re- 
tractor, and the fascia was set aside with forceps. The 
femoral artery was dissected from the femoral vein 
and ligated twice with 2-0 silk surgical sutures, 
marked with surgical clips, and then divided at a 
point just under the rectus abdominis, about 2.0 cm 
proximal to the origin of the superficial epigastric 
artery. The incision was then closed with 2-0 silk 
cutting sutures, and the animals were returned to 
their cages. 
Experimental design. For the succeeding 10 
days after ligation, daily subcutaneous injections of 1 
ml saline solution or 0.05 mg heparin (100 mg/ml, 
Upjohn, Kalamazoo, Mich.) in 1 ml saline solution 
(n = 13), or 1 txg recombinant human aFGF (ap- 
proximately 60 ixg/ml; gift of W. Burgess, American 
Red Cross, Rockville, Md.) with or without 0.05 mg 
heparin in 1 ml saline solution (n = 5) were admin- 
istered just distal to the point of femoral artery liga- 
tion. On completion of the 10-day treatment regi- 
men, the animals were reanesthetized with sodium 
pentobarbital (0.1 ml/100 g of 64.8 mg/ml stock) 
via intraperitoneal injection, subjected to the assays 
described below, and then killed by pentobarbital 
overdose. 
Angiography. For the performance of contrast 
angiography, a vertical abdominal incision was made 
along the midline. The internal organs were retracted 
laterally, and a 20 gauge 11/4-inch catheter was placed 
in the abdominal orta just distal to the origin of the 
renal arteries. A 2 ml bolus ofmeg!umine diatrizoate 
(Renografin-76, Squibb Diagnostic, New Bruns- 
wick, N.J.) was injected with a 3 ml syringe over 15 
seconds. An arteriogram (80 KPV, 15 mA, 1/20 ms) 
was taken immediately using 3M XUD film in a 
Kodak cassette with double standard intensifying 
screens and developed in a Kodak X-Omat machine. 
Histologic analysis. Ipsilateral and mirror-im- 
age contralateral biopsies were taken of the proximal 
one third of the quadriceps skeletal muscle distal to 
the vascular ligation point and of the fibrofatty tis- 
sues that intervened between the vascular ligation 
point and the skeletal muscle, as per the criteria 
proposed by Longland. 2s Additional lower leg gas- 
trocnemius biopsies were taken in an equivalent fash- 
ion. These specimens were fixed in a 10% buffered 
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Fig. 1. Percent PCNA labeling per total cell nuclei. Biop- 
sies were tal¢en of fibrofatty tissues distal to the point of 
vascular ligation 10 days after vascular ligation, after daily 
administration f one of the following: 1 ml saline solution 
(n = 13); 0.05 mg heparin in I ml saline solution (n = 13); 
1 I~g aFGF (n = 5); or I ~g recombinant human aFGF and 
0.05 mg heparin in 1 ml saline solution (n = 5). Histo- 
gram depicts PCNA labeling as percentage of total cell 
nuclei that is increased in heparin-treated group, and is 
increased to a greater extent in aFGF and aFGF/heparin 
groups, compared with saline solution controls. Error bars 
represent SEM. 
formalin solution (Sigma Chemicals, St. Louis). He- 
matoxylin and eosin (Sigma Chemicals) preparations 
were made, and the mean number of vessels per 
microscopic field (100×) was determined in a 
blinded fashion from counts of three separate, ran- 
domly selected fields for each animal. Skeletal muscle 
samples were also stained as previously described for 
alkaline phosphatase, 29 a marker for capillaries, and 
underwent similar analysis. 
Proliferating cell nuclear antigen (PCNA) 
analysis. Separate, fresh tissue biopsies (1 cm 3) were 
taken of hind limb tissues found distal to the vascular 
ligation site as described above. These specimens 
were fixed in a 10% formalin-buffered solution (Sig- 
ma Chemicals). The monoclonal antiproliferating 
cell nuclear antigen antibody, clone PC10 (Boehr- 
inger Mannheim, Indianapolis), was detected immu- 
nohistochemically using the Elite Vectastain ABC kit 
(Vector Labs, Burlingame, Calif.). All manipulations 
were performed at room temperature. Deparafflnized 
sections were treated with 0.3% hydrogen peroxidase 
in 10 mmol /L  phosphate-buffered saline solution- 
0.3% Triton X-100 (PBST) for 30 minutes to inhibit 
endogenous peroxidase. After washing in PBST, the 
sections were incubated for 60 minutes with the 
primary antibody ( l : i00) .  After washing again in 
PBST, the sections were incubated for 60 minutes 
with the biotinylated link antibody, washed with 
PBST, and exposed to avidin with biotinylated 
horseradish peroxidase for 30 minutes. After these 
treatments, visualization of  the peroxidase was 
achieved by the diaminobenzidine method. Each 
section was then counterstained with methyl green 
(Sigma Chemicals), and examined under a trans- 
mission light microscope at either low ( i00×)  or 
high (970× oil immersion) magnification. The 
mean number of PCNA-labeled nuclei per total 
cell nuclei was determined in a blinded fashion 
from counts of  three separate, randomly selected 
fields from each animal, based on an arbitrarily 
designated egree of  brown PCNA nuclear stain- 
ing. This value was multiplied by 100 to yield 
PCNA labeling as a mean percentage of  total cell 
nuclei. The mean number of  PCNA-labeled nuclei 
per vasculature c ll nuclei was determined in an 
analogous fashion, based on the microanatomic 
localization of  these cells. Omission of  the primary 
antibody resulted in negative staining, and PCNA 
analysis of sections of  human tonsil served as a 
positive control. 
Statistical analysis. Statistical analysis of this 
data was performed using an unpaired Student test. 
Statistical significance was defined as a p value less 
than 0.0S. Results are presented as the mean + 
standard eviation, except as otherwise indicated. 
RESULTS 
Model validation. A model of peripheral isch- 
emia was created using acute unilateral ligation of the 
femoral artery in the rat, as described in the Methods 
section. Consistent femoral artery ligation was con- 
firmed in all animals studied by contrast angiogra- 
phy. There was no evidence of infarction with this 
model system as determined by histologic analysis of 
sections of both the fibrofatty and skeletal muscle 
tissues obtained istal to the vascular ligation point, 
and as determined by the absence of a significant 
increase in creatinine kinase levels obtained up to 24 
hours after ligation. A consistent ability to deliver a 
therapeutic agent in this model system was demon- 
strated in preliminary methylene blue studies (n = 5) 
in which 1 ml of dye was injected as described in the 
Methods section and resulted in staining of the ipsi- 
lateral compartment or contralateral hind limb or 
intramuscular compartment. 
PCNA analysis o f  angiogenic therapy. Mito- 
genic activity induced by the various treatment regi- 
mens was determined by PCNA analysis of the fibro- 
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Fig. 2. Photomicrographs (original magnification, 400×) of PCNA immunohistochemical 
preparations after various treatment regimens. Biopsies of fibrofatty tissue distal to the point of 
vascular ligation were obtained 10 days after vascular occlusion in animals treated with daily 
administration ofone of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml 
saline solution (n = 13); I txg aFGF (n = 5); or 1 ~zg recombinant human aFGF and 0.05 mg 
heparin in 1 ml saline solution (n = 5). Saline solution controls (A) demonstrate predominant 
methyl green counterstain (blue appearance) and almost no brown PCNA labeling. PCNA 
labeling is increased in heparin-treated rats (B) and is increased to a greater extent in aFGF- 
treated animals (C) and aFGF/heparin-treated animals (D). Red blood cells are visible within 
vasculature (arrows) that is delineated by PCNA labeling. Labeling of vascular endothelial cells 
(arrows) is visible in aFGF/heparin-treated tissues (E) viewed at higher magnification (original 
magnification, 1000x). 
fatty tissues obtained distal to the vascular ligation 
point. PCNA labeling was significantly increased in 
the heparin treatment group compared with the sa- 
line solution control group and was increased to an 
even greater extent by the administration o f  aFGF 
with or without heparin (Fig. 1). PCNA labeling 
determined as a percentage o f  total cell nuclei after 
the 10-day treatment period was 5% _+ 1%, 31% -+ 
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Fig. 3. Percent PCNA labeling per vascular cell nuclei. 
Biopsies were taken of fibrofatty tissues distal to the point 
of vascular ligation 10 days after vascular ligation, after the 
daily administration f one of the following: 1 ml saline 
solution (n = 13); 0.05 mg heparin in 1 ml saline solution 
(n = 13); 1 t~g aFGF (n = 5); or 1 ~g recombinant human 
aFGF and 0.05 mg heparin in I ml saline solution (n = 5). 
Histogram depicts PCNA labeling as percentage of vascu- 
lar cell nuclei that is increased in heparin-treated group, 
and is increased to a greater extent in aFGF and aFGF/ 
heparin groups, compared with saline solution controls. 
Error bars represent SEM. 
16% (p < 0.01 vs saline solution), 66% _+ 4% (p < 
0.001 vs saline solution) and 66% - 6% for the saline 
solution, heparin, aFGF, and aFGF/heparin treat- 
ment groups, respectively. The aFGF and aFGF/  
heparin treatment groups both demonstrated a sig- 
nificantly (p < 0.05) greater level of PCNA labeling 
compared with e heparin-treated group. Equiva- 
lent sections obtained from ligated, untreated (naive) 
animals demonstrated PCNA activity that was not 
significantly different han that demonstrated in sa- 
line solution control animals. PCNA labeling in non- 
ischemic, untreated controls was less than 1% of total 
cell nuclei (data not shown). 
The PCNA labeling in sections obtained from 
saline solution-treated animals was scarce and scat- 
tered (Fig. 2, A). PCNA labeling of sections ob- 
tained from animals treated with heparin, aFGF, or 
aFGF/heparin clearly delineated capillaries and 
other small vessels, although labeling was not limited 
to these structures (Fig. 2, B to D). The density of 
PCNA labeling of capillaries and other vascular struc- 
tures appeared to be greater in the sections obtalncd 
from aFGF- and aFGF/heparin-treated animals 
compared with sections obtained from heparin- 
treated animals. Correspondingly, PCNA labeling as 
determined as a percentage ofvasculature-related c ll 
nuclei (Fig. 3) was as follows: saline solution, 7% +_ 
2%; heparin, 21% +-- 8% (p < 0.02 vs saline solution); 
aFGF, 67% +- 9% (p < 0.001 vs saline solution) and 
aFGF/heparin 83% ___ 5% (p < 0.05 vs aFGF alone). 
Both aFGF treatment groups demonstrated signifi- 
candy (p < 0.001) greater PCNA labeling of vascular 
cell nuclei than did the heparin-treated group. Fur- 
thermore, the PCNA labeling of vascular cell nuclei 
was significantly greater in the aFGF/heparin group 
compared with the aFGF alone treatment group (p < 
0.05). 
Histologic assessment of  angiogenic therapy. 
Tissue vascularity was also significantly increased in 
all three treatment groups compared with the saline 
solution control group (Fig. 4). The number of ves- 
sels per microscopic field in fibrofatty tissue sections 
was as follows: saline solution, 10 _ 4; heparin, 13 _+ 
4 (p < 0.05 vs saline solution); aFGF, 26 _ 8 (p < 
0.001 vs saline solution); and aFGF/heparin 36 _ 8 
(p < 0.001 vs saline solution). The increase in vessel 
number per field in the aFGF group and the aFGF/  
heparin group were both significantly greater (p < 
0.001) than that found in the heparin group. There 
was no evidence of infarction, myointimal hyperpla- 
sia, or neoplastic hanges in any fibrofatty tissue 
sections (Fig. 5). 
Similar findings were made in the histologic as- 
sessment of capillary density in the skeletal muscle 
tissue distal to the vascular ligation point, as deter- 
mined by alkaline phosphatase analysis (Fig. 6). The 
number of capillaries per microscopic field in skeletal 
muscle tissue sections was as follows: saline solution, 
76 + 7; heparin, 100 + 23 (p < 0.05 vs saline 
solution); aFGF, 114 _ 15 (p < 0.001 vs saline 
solution); and a_VGF/heparin, 126 +_ 30 (p < 0.001 
vs saline solution). There was similarly no evidence of 
infarction, myoinfimal hyperplasia, or neoplastic 
changes in any skeletal muscle tissue sections. 
Examination of the contralateral limb or the ipsi- 
lateral gastrocnemius (n = 6 animals) demonstrated 
no increase in vascularity despite the presence of a 
significant angiogenic effect in the treated ipsilateral 
tissues. Animals that were injected with saline solu- 
tion demonstrated no increase in vascularity when 
compared with noninjected controls (data not 
shown). 
DISCUSSION 
Potentiation of  angiogenesis. It has been hy- 
pothesized that ischemia initiates angiogenesis by 
causing the release of growth factors that are stored 
intracellularly or are bound to the extraccllular ma- 
trix. 17-2°,3° Increased expression of endogenous FGF 
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Fig. 4. Vascular density (fibrofatty tissue). Biopsies of fibrofatty tissues distal to the point of 
vascular ligation were obtained 10 days after vascular occlusion in animals treated with daily 
administration fone of the following: 1 ml saline solution (n = 13); 0.05 mg heparin in 1 ml 
saline solution (n = 13); 1 ~tg aFGF (n = 5); or 1 ~tg recombinant human aFGF and 0.05 mg 
heparin in 1 ml saline solution (n = 5). Vessel number was determined per low power field 
(100 × ) as described in Methods ection. Representative low power fields are depicted for (A) 
saline solution group and (B) aFGF/heparin-treated animals. C, Histogram depicts vessel 
number per microscopic field that is increased in heparin-treated group, and is increased to a 
greater extent in the aFGF and aFGF/heparin groups, compared with saline solution controls. 
Error bars represent SEM. 
may represent an alternative mechanism underlying 
the stimulation ofangiogenesis in these settings. 31-33 
This increased endogenous FGF expression, and an 
associated increase in mitogenic activity appears, 
however, to be late in onset and transient, approach- 
ing baseline levels within 1 week of  vascular occlu- 
sion. ~,2,31-33 Our current observations of low levels of 
PCNA labeling 10 days after vascular ligation in 
saline solution-treated controls support these find- 
ings. The significant enhancement of angiogenesis 
caused by the administration of exogenous human 
recombinant aFGF and heparin the current studies 
furthermore tend to confirm that the endogenous 
response to ischemia is a submaximal one. 
PCNA data included in the present study demon- 
strate that the increases in vessel number  noted in 
heparin- and aFGF-treated animals was associated 
with increased cell proliferative activity compared 
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Fig. 5. Photomicrographs (original magnification, 400×) of fibrofatty tissue after various 
treatment regimens. Biopsies of fibrofatty tissues distal to the point of vascular ligation were 
obtained 10 days after vascular occlusion in animals treated with daily administration fone of 
the following: I ml saline solution (n = 13); 0.05 mg heparin in 1 ml saline solution (n = 13); 
1 ixg aFGF (n = 5); or 1 Ixg recombinant human aFGF and 0.05 mg heparin in 1 ml saline 
solution (n = 5), and prepared as described in Methods ection. Vascular density compared 
with saline solution-treated controls (A) is increased in heparin-treated rats (B), and is increased 
to a greater extent in aFGF-treated animals (C) and aFGF/heparin-treated animals (D). Arrows 
depict vasculature. 
with controls, suggesting that this increased vascular- 
ity is in fact a result of new vessel growth as opposed 
to distention of a preexistent vasculature. This dem- 
onstration of the relative mitogenicity of  these angio- 
genie regimens has, to our knowledge, not previ- 
ously been described. Our observation that PCNA 
labeling clearly delineated, but was not limited to, 
vascular structures was anticipated because aFGF is a 
mitogen for a variety of mesenchymal cells. How- 
ever, the inclusion of a vascular PCNA score and 
histologic assessment of the number of vessels were 
designed to specifically quantify vascular mitogenesis 
and angiogenesis. These data thus reflect he angio- 
genicity, as well as the mitogenicity, of the reported 
treatment regimens. 
The efficacy of heparin therapy alone in stimulat- 
ing angiogenesis in the present study confirms previ- 
ous observations of the angiogenic potential of hep- 
arin in vivo. 9,22,24 Because heparin has no in vitro 
mitogenic apacity of its own, the efficacy of heparin 
therapy in these studics may be a rcsult of an interac- 
tion of heparin with endogenous FGF or other 
growth factors. 12,19,34,a5 However, the intermediate 
angiogenic response rate noted with hcpatin therapy 
alone compared with aFGF/heparin therapy would 
again suggest hat endogenous aFGF is capable of 
stimulating only submaximal levels of angiogenesis. 
Acidic and basic FGF administration have both 
previously been demonstrated to stimulate angio- 
genesis in a number of in vivo studies. These have 
included nonischemic models of chick chorioallan- 
toic membrane, rabbit cornea, vascular adventitia, 
and rat renal capsule, as well as models of peripheral, 
myocardial, and cerebral ischemia. 16,36-4° Similar re- 
suits have been reported with the administration of 
vascular endothelial growth factor. 3s These previous 
results have not generally reflected an even greater 
mitogenic effect demonstrated by these growth fac- 
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tors in vitro. 12'34 The stimulation of new vessel 
growth reported in the current s udy compared with 
an even greater increase in mitogenic activity, as 
determined by PCNA studies, suggests that a diver- 
gence may exist between the mitogenic and angio- 
genie potential ofaFGF in vivo. In this regard, anglo- 
genesis, or new vessel development, can be viewed as 
a complex process that could conceivably be ex- 
pected to lag behind increases in cell replication 
rates. 
The aFGF/hepar in  regimen. Dosing of aFGF 
for our experiments was based on previous in vitro 
and in vivo determinations of the optimal FGF con- 
centrations required for mitogenesis z2'3<4~ and the 
pharmacoldnetics of in vivo administration. 42 Prelim- 
inary methylene blue dye experiments in which the 
initial volume of  distribution of agents administered 
in the rat hind limb inguinal region was determined 
to be approximately 1 ml were also incorporated into 
dosing calculations. Cell culture studies suggested 
that a minimal aFGF tissue concentration f 10 to 20 
ng/ml  resulted in peak cell growth rates ~2,34 and rat 
pharmacokinetic studies suggested that parenterally 
administered aFGF clearance was characterized by a 
half-life of approximately 15 minutes. 42 These data 
yielded the total estimated aily dose requirement of 
1 jxg used in these studies. 
Because of the cofactor function of hcparin for 
aFGF in vitro, heparin coadministration was thought 
at the outset of this investigation to represent a key 
component of the angiogenic therapy with aFGF. 
Heparin dosing for our experiments was based on in 
vitro data that suggested that a heparin concentra- 
tion of 0.05 mg/ml  was required for protein stabili- 
zation and maximal potentiation of the mitogenicity 
ofaFGF.  1344 In comparison, in the study by Pu et 
al.4 in which the angiogenic potentiation was less 
than that noted in the current study, the heparin 
dosages were on the order of  one-ten thousandth 
the heparin-to-aFGF ratio and one-thirtieth the 
heparin-to-volume ratio used in our study. Al- 
though the excessive heparin administration may 
potentially lead to anticoagulant toxicity with this 
agent, and additional evidence has suggested that 
high heparin dosages may be inhibitory to cell 
growth, 4a these complications were not noted in 
our study. 
Contrary to our initial expectations, our data 
demonstrate hat although heparin did enhance the 
angiogenic potential of exogenous aFGF, aFGF was 
capable of inducing angiogenesis without heparin 
coadministration. These observations uggest hat 
the interaction of  exogenous aFGF with endogenous 
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Fig. 6. Vascular density (skeletal muscle tissue). Biopsies 
of skeletal muscle tissue distal to the point of vascular 
ligatiou were obtained 10 days after vascular occlusion in 
the animals treated with daily administration fone of the 
following: 1 ml saline solution (n = 13); 0.05 mg heparin 
in 1 ml saline solution (n = 13); 1 big aFGF (n = 5); or 1 
~tg recombinant human aFGF and 0.05 mg heparin in 1ml 
saline solution (n = 5). Vessel number was determined per 
low power field (100×) as described in Methods ection. 
Histogram depicts vessel number per microscopic field that 
is increased in the heparin-treated group, and is increased 
to a greater extent in aFGF and aFGF/heparin group, 
compared with saline solution controls. Error bars repre- 
sent SEM. 
heparan sulfate proteoglycans in the extracellular ma- 
trix may allow for aFGF activity in the absence of 
heparin administration. On the other hand, the lack 
of an increase in vessel number in our saline solution- 
treated or noninjected animals further substantiates 
our conclusion that these angiogenic effects are at- 
tributable to heparin and aFGF rather than the injec- 
tion or surgical procedure alone. 
Local administration of growth factor may maxi- 
mize the potentiation of angiogenesis conferred by 
the chemotactic properties of  these growth factors. 2~ 
On the other .hand, systemic administration of  
growth factor may be inherently disadvantageous 
because delivery of a systemically administered agent 
will by definition be proportionately decreased to the 
targeted ischemic tissues. Furthermore, systemic or 
intravascular therapy may lead to inappropriate an- 
giogenesis at remote foci, as was noted by Isner et 
al.44 in a clinical study using intraarterial delivery of 
vascular endothelial growth factor via a plasmid vec- 
tor. Theoretically, such sensitive areas as the retina, 
synovium, or occult tumors could therefore b inap- 
propriately targeted by these approaches. Direct, lo- 
cal administration ofaFGF and heparin was therefore 
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used in our studies, and in fact demonstrated local- 
ization of angiogenic effect. 
L imitat ions of  study design. Maximal dosages 
of aFGF and heparin were used in the current study 
to increase the likelihood of stimulating angiogene- 
sis. It  is possible that smaller aFGF or heparin dos- 
ages might have produced similar increases in a gio- 
genesis as those demonstrated. Similarly, daily 
repetitive dosing of aFGF/heparin were used based 
on extrapolation from in vitro data, as explained 
above. It is nevertheless conceivable that less-fre- 
quent dosing or even single-dose therapy might also 
have been effective. Although local, percutaneous 
treatment could have presented a risk of variable or 
widespread elivery of the agent, our preliminary 
methylene blue marker studies and the reproducible 
and localized effects of our angiogenic agents sug- 
gested that this was not the case. 
Previous studies have examined angiogenic stim- 
ulation in models of both acute and chronic isch- 
emia. Our model is based on previous models of 
acute lower lir~b ischemia. 3-s,26,as The current study 
was specifically designed to affect angiogenesis dur- 
ing the early, "latent" period of acute ischcmia, be- 
fore the development of native collateralization. ~,2 
Such acute therapy may be clinically applicable in 
accelerating and enhancing collateralization immedi- 
ately after vascular occlusion, when ischemia is the 
most severe. Although it can be argued that this 
strategy failed to allow for "stabilization" of endoge- 
nous angiogenic mechanisms, the demonstration of
enhanced angiogenesis n this acute phase may nev- 
ertheless reflect an even more positive outcome than 
portrayed, because maximal stimulation of the en- 
dogenous angiogenic mechanisms during this acute 
time frame may represent a bias against significant 
angiogenic therapy outcomes. 
Limitat ions of  angiogenic assays. We believe 
that our reliance on PCNA and histologic assess- 
ments of  angiogenic responses to the therapeutic 
regimens described, as opposed to hemodynamic or 
perfusion parameters, is justified as the most direct 
measurements of the angiogenic response to these 
regimens. In fact, recent studies suggest that the 
increased perfusion previously noted with angiogenic 
therapy may in part be related to the hemodynamic 
and vasodilator properties of these regimens. 4~47 
The current data are therefore important in verifying 
the specific angiogenic potentials of aFGF and hepa- 
rin. By the same token, our results are consequently 
limited to the extent hat they represent data regard- 
ing angiogenesis only and do not reflect the previ- 
ously reported ability of various angiogenic regimens 
tO augment perfusion of ischemic tissues. Unfortu- 
nately, the angiographic and microsphere studies we 
performed yielded a degree of variability that did not 
permit a meaningful interpretation of these data. In 
contrast, the low intragroup variability and close cor- 
relation of results in the control groups, derived from 
blinded analysis of anatomically defined biopsies, 
suggests an acceptable degree of reproducibility in 
the assays performed. The comparative data that cor- 
roborate the vascularization and mitogenicity in- 
duced by aFGF and heparin presented in the current 
study document for the first time that increases in 
perfusion oted with heparin, and to a greater extent 
with aFGF/heparin therapy, are most likely the re- 
sult of increased cell replication and new vessel devel- 
opment, or true angiogenesis. These data suggest 
that therapeutic angiogenesis may be an effective 
means of increasing per fusion in the acute ischemic 
setting. 
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